GlaxoSmithKline's biologic Nucala, or mepolizumab, has been approved by the FDA as a treatment for a subset of patients with hypereosinophilic syndrome who are at least 12 years old. The IL-5 antagonist has previously received FDA approval as a treatment for pediatric patients with severe asthma, eosinophilic asthma, and eosinophilic granulomatosis with polyangiitis.
Glaxo's Nucala approved for hypereosinophilic syndrome
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.